Effect of benralizumab on airway mucus, air-trapping and airway volume, assessed by functional respiratory imaging in severe eosinophilic asthma

Conemans,L.,Groenen,M.,Simons,S.,Spruit,M.,Hajian,B.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa5367

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Introduction: Severe eosinophilic asthma (SEA) responds favorably to benralizumab, owing to its anti-eosinophilic effects. However, its influence on airway physiology is less well understood. Using Functional Respiratory Imaging (FRI), this study explored benralizumab's short-term effects on airway pathology in SEA. Methods: A single-arm trial involving 20 SEA patients that started benralizumab, with HRCT scans at FRC and TLC at baseline, 4, and 12 weeks, was performed. FRI-based outcomes included mucus score (MS), air-trapping (AT) and airway volume (SIVAW). Spirometry, oscillometry, bodyplethysmography, FeNO, ACQ and SGRQ were other outcome parameters. Data were analyzed using linear mixed models. Results: Significant (p<0.05) LSM differences in MS (–0.52 point) and AT (–5.5 points) were observed at week 12 (figure shows an individual response). An inverse relationship between MS and FEV1 was observed, where each MS point decrease resulted in a 1.33% increase in FEV1. Significant improvements in SIVAW were noted by week 12 at TLC (+14%) and FRC (+27%). Conclusion: Benralizumab decreases airway mucus, increases airway volume and reduces air-trapping in SEA, as shown by FRI. FRI visualizes the capability of benralizumab to modify mucus plugging in the short-term. This could support selection and monitoring of biologic therapies for SEA.

respiratory system